Why is Bluebird sitting on results of a CAR-T drug critical to its future?
For the past year, Bluebird Bio has been tracking long-term outcomes from multiple myeloma patients treated with its experimental CAR-T therapy called bb2121. So, why haven’t those data been disclosed publicly?
To do so would be a “distraction to the team,” said Bluebird CEO Nick Leschly, referring to the company’s employees. Not everyone agrees. As Adam Feuerstein notes, the success or failure of bb2121 will depend on its ability to keep patients in remission and prolong survival.
By sitting on these important data, Bluebird is raising questions about bb2121’s future.
Read more.
To do so would be a “distraction to the team,” said Bluebird CEO Nick Leschly, referring to the company’s employees. Not everyone agrees. As Adam Feuerstein notes, the success or failure of bb2121 will depend on its ability to keep patients in remission and prolong survival.
By sitting on these important data, Bluebird is raising questions about bb2121’s future.
Read more.
No hay comentarios:
Publicar un comentario